Prokarium
Prokarium is a clinical-stage biopharmaceutical company that develops microbial immunotherapies for the treatment of solid tumors. The company utilizes a proprietary strain of bacteria, ZH9, as a platform to target the tumor microenvironment and elicit anti-tumor immunity. Its lead clinical program focuses on treating non-muscle invasive and muscle-invasive bladder cancer.
Biotechnology
Healthcare
Oncology
Biopharmaceuticals
Funding summary
- Total raised
- €33.1M
- Funding rounds
- 2
Investors in Prokarium
Investors on record for Prokarium. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Prokarium?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors